Saturday, May 26, 2012

Brain Scan for Alzheimer's


Caregivers, and healthcare professionals, here is some great information


Here is a great dementia resource for caregivers and healthcare professinals,


Your residents will love the Amazon Kindle Fire




Here is information on being the best caregiver you can be


Here is a way for nurses administrators, social workers and other health care  professionals to get an easyceu or two


Follow alzheimersideas on twitter

The Dementia Caregiver's Little Book of Hope [Kindle Edition]


Technology Review


A recently approved plaque-tracking dye can improve doctors' ability to identify Alzheimer's.


by Susan Young


Beginning next month, doctors can use a brain scan to better diagnose Alzheimer's. The U.S. Food and Drug Administration recently approved a fluorescent dye that binds to amyloid plaques, a physical hallmark of the disease, as a diagnostic tool.  


Currently, doctors cannot be certain whether or not a patient's brain is riddled with amyloid plaques until after the patient's death. But now, clinicians can use a weakly radioactive dye to search for the presence of plaques in a living patient. The dye binds to the starchy amyloid that builds up in the brains of Alzheimer's patients and can be visualized in a PET scan. The FDA approved the scan as a method for estimating plaque content in the brains of people exhibiting cognitive decline. The presence or absence of plaques in a patient with forgetfulness, confusion, or other signs of neurological trouble could help doctors with their diagnoses. 
Although scientists do not know whether or not the plaques are the cause of Alzheimer's, the plaques are strongly correlated with symptoms of dementia. Elderly people with the plaques have a more rapid mental decline than the elderly who don't have the plaques. And even though doctors cannot treat Alzheimer's, diagnostic tools like the plaque-marking dyes will help them identify patients with the disease, as well as those who do not have it but exhibit signs of mental decline due to other problems.
"A positive scan would add more weight to our bedside diagnosis," says Liana Apostolova, an Alzheimer's specialist at the University of California, Los Angeles. She says the technique could be useful in diagnosing patients with unusual forms of the disease and patients whose symptoms may be caused by other conditions, such as drug side effects or depression. "If a patient's cognitive impairment is purely due to depression, then a negative amyloid scan would help ascertain that," Apostolova says.  


The new dye and other plaque-marking dyes have been used in clinical research for years, but Eli Lily, whose subsidiary Avid Radiopharmaceuticals produces the diagnostic agent, is the first to bring the technique to the doctor's office. Some experts are still concerned that the clinical use of the dye might be a bit premature, since the presence of the plaques isn't enough to confirm an Alzheimer's diagnosis. In fact, the amyloid deposits are often found in older people with normal mental ability and could be associated with other neurologic conditions. For now, the Avid dye is only approved to be used to rule out Alzheimer's (if no plaques are detected, a doctor can be confident the patient doesn't have the disease).

"I think it puts the clinician in a bind," says Ronald Petersen, director of the Mayo Clinic's Alzheimer's Disease Research Center. If a scan is negative, then a doctor can tell a patient that amyloid is not contributing, but if a scan is positive, what should a clinician do? "The FDA nor the company says anything about the meaning of a positive scan," says Petersen. "The data is not out there."
Petersen and others agree, however, that plaque-detecting diagnostics are critical for Alzheimer's research. The dyes enable researchers to determine which participants carry plaques and thus design better trials for plaque-attacking drugs. Within the trials, plaque tracers can be used to monitor the amount of plaque in a participant's brain during the course of treatment.
The tracers can also help the field elucidate the causes and disease mechanisms of Alzheimer's, which will be key to treating or preventing the disease. Researchers can study people who have amyloid plaques and monitor their cognitive abilities over time. From the pool of cognitively normal elderly with a positive scan, knowing who "develops Alzheimer's disease and who doesn't will help us explore disease susceptibility and resistance, identify all genetic risk factors and the early metabolic changes, so we can then target these specific processes with drugs," Apostolova says. "Diagnoses can be helpful, but we want therapeutics."
More than five million people in the United States have Alzheimer's, and that number is expected to double in coming years, according to the U.S. Department of Health and Human Services. By their early 70s, as many as 30 percent of people have amyloid plaques in the brain, says Michael Weiner, principal investigator of the Alzheimer's Disease Neuroimaging Initiative, which tests imaging techniques as well as biomarkers for Alzheimer's that could be found in the blood or cerebrospinal fluid.
The new dye-based scans "are going to create greater public consciousness of the disease, and that will have a big impact," says Weiner.



Print




Friday, May 25, 2012

Why you should beat smoking


Health care professionals and caregivers of people with dementia and other neurological problems, here is some information you will find useful.

Smoking has been shown to be bad for all people. It affects every organ in your body in a negative way. There is nothing good about it. Yet millions of people still smoke despite the risk they put themselves at.

If you or a loved one have been a lifelong smoker, you are at a huge risk for developing dementia sooner rather than later. Of course you or a loved one may escape the clutches of dementia, but you could develop heart disease, lung cancer or kidney disease by smoking.

What is really bad is if your loved one already has dementia. There are just so many risks if he or she continues to smoke. First of all, the dementia will progress more rapidly than if he or she quit. It may be hard to get him or her to stop because he or she is so used to doing it

Also imagine the safety risk. They could easily start a fire by being careless lighting the cigarette. Or he or she could fall asleep while his or her cigarette is still burning.

If you, the caregiver, smoke, then your loved one with dementia undoubtedly will have some negative effects from the second hand smoke. So you and they need to be beating smoking before it is too late.

Thursday, May 24, 2012

USF Health part of national resveratrol study for Alzheimer’s disease


Here is a great dementia resource for caregivers and healthcare professionals,


You will love the Amazon Kindle Fire


Here is information on being the best caregiver you can be


Here is a way for nurses administrators, social workers and other health care professionals to get an easyceu or two


Follow Alzheimers1 on twitter

USF

Can a component found in red wine help change the course of Alzheimer’s disease?


The USF Health Byrd Alzheimer’s Institute has been selected as one of the sites for a federally-sponsored clinical study testing whether resveratrol can alter or delay memory deterioration and daily functioning in people with mild to moderate Alzheimer’s disease.


Some of the highest levels of resveratrol are found in red wine and the skin of red grapes, but the plant-derived compound is also present in chocolate, berries, tomatoes and peanuts.


The double-blind, placebo-controlled Resveratrol for Alzheimer’s Disease Study, supported by the National Institute on Aging, will be conducted at 26 sites across the United States affiliated with the Alzheimer’s Disease Cooperative Study. Each research site, including USF’s, will enroll up to 10 participants


Amanda Smith, MD, medical director at the Byrd Alzheimer’s institute, leads the USF site study on the safety, tolerability and effectiveness of the natural compound (pure resveratrol in capsule form). The one-year trial has begun recruiting participants.


“This is an exciting study for a couple of reasons,” Dr. Smith said. “First, it is a naturally-occurring substance, and that is sometimes more appealing to participants. Secondly, it approaches the disease from a different angle than many other treatments being tested, so it could be another weapon in the multi-pronged approach to treating Alzheimer’s.”


Resveratrol activates a class of enzymes known as sirtuins, which are involved in modulating metabolism and may affect regulatory pathways of diseases of aging. Pre-clinical research and pilot clinical studies suggest the compound may prevent diabetes, ward off cardiovascular disease, act as a natural cancer fighter, and prevent memory loss, but there has been no large definitive study of its effects in humans.


“It’s a hot topic of research interest these days,” said Min You, PhD, associate professor in the USF Health Department of Molecular Pharmacology and Physiology, whose published studies of resveratrol in mice found that the substance may prevent alcoholic fatty liver disease.


“SIRT1, one of the targets of resveratrol, is a metabolic sensor in every tissue of the body, including the heart, liver and brain,” Dr. You said. “Resveratrol keeps metabolic processes in balance and plays a role in longevity.”
Dr. You, who has studied resveratrol and its regulatory pathways for nearly eight years, believes the compound may have greater potential to prevent than treat age-related diseases like Alzheimer’s, diabetes, obesity and heart disease. “It’s quickly removed from the bloodstream when consumed, so you’d likely have to take a very high amount of resveratrol to reverse pathology,” she said. “However chronic consumption of low-dose resveratrol could be good as a preventive approach.”




For more information on the Resveratrol for Alzheimer’s Disease Study, call the Byrd Institute at (813) 974-4355.









Tuesday, May 22, 2012

Alzheimer's plan and drug trials


Here is a great dementia resource for caregivers and healthcare professionals,


You will love the Amazon Kindle Fire


Here is information on being the best caregiver you can be


Here is a way for nurses administrators, social workers and other health care professionals to get an easyceu or two


Follow Alzheimers1 on twitter

Medpage Today

Friday, May 18, 2012

Researchers move closer to delaying dementia


Here is a great dementia resource for caregivers and healthcare professionals,


You will love the Amazon Kindle Fire


Here is information on being the best caregiver you can be


Here is a way for nurses administrators, social workers and other health care professionals to get an easyceu or two


Follow Alzheimers1 on twitter

UQ News

Scientists at UQ's Queensland Brain Institute are one step closer to developing new therapies for treating dementia.



QBI's Dr Jana Vukovic said the work was aimed at understanding the molecular mechanism that may impair learning and memory in the aging population.


“Aging slows the production of new nerve cells, reducing the brain's ability to form new memories,” said Dr Vokovic, who performed the work in the laboratory of Professor Perry Bartlett, the Director of QBI at The University of Queensland.


"But our research shows for the first time that the brain cells usually responsible for mediating immunity, microglia, have an inhibitory effect on memory during aging.


“Furthermore, they have shown that a molecule produced by nerve cells, fractalkine, can reverse this process and stimulate stem cells to produce new neurons.”


The discovery, published in The Journal of Neuroscience today, came after QBI scientists observed that the increased production of new neurons in mice that were actively running was due to the release of fractalkine in the hippocampus – the brain structure responsible for specific types of learning and memory.

Professor Bartlett said it had been known for some time that exercise increased the production of new nerve cells in the hippocampus in young and even aged mice.

“But this study found that it is fractalkine that appears to be specifically mediating this effect by making the microglia produce factors that activate the stem cells that produce new nerve cells,” he said.

“Once the cells are activated they divide and produce new cells, which underpin the animal's ability to learn and form memories.



"This means that fractalkine may form the basis for the development of future therapies.

“The discovery is especially exciting because we have found that older animals suffering cognitive decline showed significantly lower levels of fractalkine.

“We are seeking ways of increasing fractalkine levels in patients with cognitive decline, and hoping this may be a new frontline therapy in treating dementia.”


Dr Vukovic said that until relatively recently, it was thought the adult brain was incapable of generating new neurons.

“But work from Professor Bartlett's laboratory over the past 20 years has demonstrated that the brains of adult animals, including humans, retain the ability to make new nerve cells,” she said.


“The challenge is to find out how to stimulate this production in the aged animal and human where production has slowed.”

The latest work was a significant step toward achieving this goal, she said.


The article published today is titled Microglia modulate hippocampal neural precursor activity in response to exercise and aging. Its authors are Jana Vukovic, Michael J. Colditz, Daniel G. Blackmore, Marc J. Ruitenberg, Perry F. Bartlett




Wednesday, May 16, 2012

Study Links Depression And Dementia


Here is a great dementia resource for caregivers and healthcare professionals,


You will love the Amazon Kindle Fire


Here is information on being the best caregiver you can be


Here is a way for nurses administrators, social workers and other health care professionals to get an easyceu or two


Follow Alzheimers1 on twitter

Huffington Post

People who suffer from chronic depression throughout their lives are more likely to develop dementia compared with people who aren't depressed, according to a study released Monday.


The study, by California researchers, sheds light on whether depression might cause dementia and Alzheimer's disease, or if it is merely an early sign of memory loss and other problems associated with dementia. Alzheimer's disease is the leading cause of dementia; the second-leading cause is impaired blood supply to the brain, resulting in what is known as vascular dementia

"It's quite clear depression late in life can be an early sign of Alzheimer's," explained Rachel Whitmer, a study researcher and an investigator at the Kaiser Permanente Northern California Division of Research. "There's a lot of debate whether [depression] is really a risk factor for dementia, or if it just shows up."

The findings, published in the May issue of Archives of General Psychiatry, add to the evidence that late-in-life depression is a likely early sign of Alzheimer's disease and suggest that chronic depression appears to increase the risk of developing vascular dementia. Adequate treatment for depression in midlife could cut the risk of developing dementia. The study is the first to examine whether midlife or late-life depression is more likely to lead to either Alzheimer's disease or vascular dementia over the long term.


To look at links between depression and dementia, Dr. Whitmer and other researchers looked at 13,535 long-term Kaiser Permanente members who had enrolled in a larger study in the period from 1964 to 1973 at ages ranging from 40 to 55 years old. Health information, including a survey that asked about depression, was collected at the time.

Researchers looked at whether the same people were depressed late in life, in the period from 1994 to 2000, and then looked at whether they were diagnosed with dementia or Alzheimer's disease in 2003. The participants' average age in 2003 was 81 and 57.9% were women. The study found depression present in 14.1% of subjects in midlife only, in 9.2% in late life only and in 4.2% in both
Looking at those who later developed dementia, the study found 20.7% of study participants without depression developed dementia, compared with 23.5% of people who reported depression in midlife only and 31.4% of those who were depressed later in life. Among those who were depressed at both mid- and late-life, 31.5% developed dementia.
Researchers then did more analysis to tease out Alzheimer's diagnoses from the broader dementia category. They found people who were depressed in midlife but not late in life had no increased risk of developing Alzheimer's disease or vascular dementia. People who were depressed late in life were more likely to develop Alzheimer's while those depressed at both mid- and late life were three times as likely to develop vascular dementia.

Dr. Whitmer's research focused on people's health and how it affects brain aging. Previous studies she has conducted using Kaiser's database of long-term members, have shown that factors such as smoking, diabetes, high cholesterol and belly fat increase the risk of developing Alzheimer's and other brain diseases. A 2008 study looking at belly fat showed people who had more belly fat during middle age had higher rates of dementia when they reached old age. The finding held true even for people whose overall body weight was considered normal.




Monday, May 14, 2012

Mitochondria Dysfunction Occurs Early in Alzheimer’s Disease Prior to Memory Loss, Amyloid Deposits

Here is a great dementia resource for caregivers and healthcare professionals,


You will love the Amazon Kindle Fire


Here is information on being the best caregiver you can be


Here is a way for nurses administrators, social workers and other health care professionals to get an easyceu or two


Follow Alzheimers1 on twitter

Highlight health

Walter  Jessen
Mitochondria are specialized subunits inside a cell that produce the cell’s energy and regulate its metabolism. Research suggests that mitochondria may play a central role in neuronal cell survival because they regulate both energy metabolism and cell death pathways. Using genetic mouse models of Alzheimer’s disease, researchers from Mayo Clinic have found that mitochondria in the brain are dysfunctional early in the disease. The findings were recently published in the open access journal PLoS ONE.

Using real time imaging, scientists examined mitochondria in live neurons from three different mouse models of Alzheimer’s disease. Each of the mouse models had a different gene mutation shown to cause familial, or early-onset, Alzheimer’s disease. To evaluate the the impact of a given mutation, mitochondrial motility, distribution, ultrastructure and function in neurons and brain tissue was examined early in mouse development until the age where mice began to display memory loss and amyloid deposits formed.

Researchers used a mitochondria-specific dye and monitored axonal trafficking (i.e. motion along axons or nerve fibers). The investigators found that mitochondrial axonal trafficking is inhibited in embryonic neurons afflicted with Alzheimer’s disease, well before mice showed any memory loss or amyloid plaque formation.


Indeed, inhibition of axonal trafficking was found to be a general defect that occurred in all three mouse models of Alzheimer’s disease and was not specific for mitochondria. Nevertheless, neurons with inhibited mitochondrial trafficking were found to be more susceptible to excitotoxic cell death, a pathological process wherein nerve cells are killed by excessive neurotransmitter stimulation.
In the brains of all three mouse models of Alzheimer’s disease, mitochondria tended to lose their integrity and subsequently stopped functioning. Importantly, dysfunctional mitochondria were detected at the synapses of neurons involved in maintaining memory, suggesting a direct linkage with Alzheimer’s disease.


The scientists also applied a method called metabolomics, which measures the chemical fingerprints of specific metabolic pathways in the cell such as sugars, lipids, nucleotides, amino acids and fatty acids. The approach takes a snapshot of what is happening in the body at a given time and at a hight level of detail, and provides insight into the cellular processes that underlie a disease. For this study, the metabolomic profiles showed changes in metabolites related to mitochondrial function and cellular energy metabolism, which further confirmed that altered mitochondrial energetics is fundamental to the disease process.
The researchers identified a panel of metabolomic biomarkers. According to Eugenia Trushina, Ph.D., Mayo Clinic pharmacologist and senior investigator on the study [2]:


We are not looking at the consequences of Alzheimer’s disease, but at very early events and molecular mechanisms that lead to the disease. We expect to validate metabolomic changes in humans with Alzheimer’s disease and to use these biomarkers to diagnose the disease before symptoms appear — which is the ideal time to start treatment.

The researchers conclude by stating that Alzheimer’s disease can be viewed as a mitochondrial movement disorder with evolving energetic deficit represented by the panel of metabolomic biomarkers and that mitochondrial dysfunction is an underlying event in Alzheimer’s disease progression.
References


1.Trushina et al. Defects in mitochondrial dynamics and metabolomic signatures of evolving energetic stress in mouse models of familial Alzheimer’s disease. PLoS One. 2012;7(2):e32737. Epub 2012 Feb 29.



2.Mitochondrial Dysfunction Present Early in Alzheimer’s, Before Memory Loss. Mayo Clinic News. 2012 Feb 29.
Blog Flux Directory
alzheimersideas - whereIstand.com

Fitness is important in dementia prevention. Click below for more info